It may be useful for someone to explain to our board, how Big Pharma companies conduct their due diligence on such small cap biotech companies. 

It is not just the science people...the statisticians, sales, etc need to sign off on such deals, I am assuming, before it goes in front of the board.  The scientists may also want to solicit general feedback from key opinion leaders before they decide on what to make of the drug. 

All this is important to understand how fast Big Pharma is willing to put in a bid for RVX.  My own bias is that the FDA letter is the last box to tick for any buyer.

Thanks

Iconoclast